Ben Khelil Myriam, Godet Yann, Abdeljaoued Syrine, Borg Christophe, Adotévi Olivier, Loyon Romain
UMR1098, EFS BFC, INSERM, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, F-25000 Besançon, France.
Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.
Cancers (Basel). 2022 Jan 5;14(1):260. doi: 10.3390/cancers14010260.
Over the past decades, CD4 T cells have been considered as a supporting actor in the fields of cancer immunotherapy. Until recently, accumulating evidence has demonstrated the critical role of CD4 T cells during antitumor immunity. CD4 T cells can either suppress or promote the antitumor cytotoxic CD8 T cell responses, either in secondary lymphoid organs or in the tumor. In this review, we provide an overview of the multifaceted role of different CD4 T cell subsets in cancer immune response and their contribution during cancer therapies. Specifically, we focus on the latest progress regarding the impact of CD4 T cell modulation on immunotherapies and other cancer therapies and discuss the prospect for harnessing CD4 T cells to control tumor progression and prevent recurrence in patients.
在过去几十年里,CD4 T细胞在癌症免疫治疗领域一直被视为配角。直到最近,越来越多的证据表明CD4 T细胞在抗肿瘤免疫过程中发挥着关键作用。CD4 T细胞在二级淋巴器官或肿瘤中,既可以抑制也可以促进抗肿瘤细胞毒性CD8 T细胞反应。在这篇综述中,我们概述了不同CD4 T细胞亚群在癌症免疫反应中的多方面作用及其在癌症治疗中的贡献。具体而言,我们关注CD4 T细胞调节对免疫疗法和其他癌症疗法影响的最新进展,并讨论利用CD4 T细胞控制肿瘤进展和预防患者复发的前景。